IMUX vs. AGLE, LXRX, ESPR, SLRN, TBPH, PGEN, CTNM, BMEA, TERN, and VRCA
Should you be buying Immunic stock or one of its competitors? The main competitors of Immunic include Aeglea BioTherapeutics (AGLE), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Acelyrin (SLRN), Theravance Biopharma (TBPH), Precigen (PGEN), Contineum Therapeutics (CTNM), Biomea Fusion (BMEA), Terns Pharmaceuticals (TERN), and Verrica Pharmaceuticals (VRCA). These companies are all part of the "pharmaceutical preparations" industry.
Immunic (NASDAQ:IMUX) and Aeglea BioTherapeutics (NASDAQ:AGLE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment.
Immunic has a net margin of 0.00% compared to Aeglea BioTherapeutics' net margin of -22,195.36%. Aeglea BioTherapeutics' return on equity of -132.05% beat Immunic's return on equity.
Immunic has a beta of 1.83, meaning that its share price is 83% more volatile than the S&P 500. Comparatively, Aeglea BioTherapeutics has a beta of 2.57, meaning that its share price is 157% more volatile than the S&P 500.
Aeglea BioTherapeutics has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Aeglea BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Aeglea BioTherapeutics received 160 more outperform votes than Immunic when rated by MarketBeat users. However, 65.73% of users gave Immunic an outperform vote while only 56.57% of users gave Aeglea BioTherapeutics an outperform vote.
Immunic presently has a consensus target price of $8.50, suggesting a potential upside of 591.06%. Aeglea BioTherapeutics has a consensus target price of $17.50, suggesting a potential upside of ∞. Given Aeglea BioTherapeutics' higher possible upside, analysts clearly believe Aeglea BioTherapeutics is more favorable than Immunic.
51.8% of Immunic shares are held by institutional investors. 3.0% of Immunic shares are held by company insiders. Comparatively, 6.6% of Aeglea BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Immunic's average media sentiment score of 0.00 equaled Aeglea BioTherapeutics'average media sentiment score.
Summary
Aeglea BioTherapeutics beats Immunic on 8 of the 15 factors compared between the two stocks.
Get Immunic News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMUX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMUX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
